Generic Drugmaker Amring Providing Refunds for 340B Overcharges

Generic drug manufacturer Amring Pharmaceuticals is giving 340B covered entities refunds for overcharges on 14 products between the first quarter [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Johnson & Johnson, Astellas Each Sue to Stop Medicare Drug Price Negotiations

Johnson & Johnson and Astellas
Johnson & Johnson and Astellas are the latest drugmakers to sue in federal court to stop Medicare drug price negotiation.
Drug manufacturers Johnson & Johnson and Astellas Pharma have each asked federal district courts to strike down parts of the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

In What Could be a First, Drug Maker Gives Providers Deadline to Request 340B Overcharge Refunds

VistaPharm
Drug manufacturer VistaPharm says requests for refunds for 340B overcharges must be received before Aug. 31. No manufacturer is believed to have set such a deadline before, and it's unclear if VistaPharm is the first to say refunds are available upon request.
Generic and over-the-counter drug manufacturer VistaPharm said in a public notice this week that it has identified 340B covered entities [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

UPDATED: Astellas and AstraZeneca Make 340B Contract Pharmacy Moves

Astellas Pharma
Astellas is the third drugmaker to loosen or end its 340B contract pharmacy restrictions in Arkansas and Louisiana in response to state laws.
Drug manufacturers Astellas and AstraZeneca announced today separate contract pharmacy policies for 340B providers that will go into effect in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

ASAP 340B, PhRMA and NACHC’s 340B Alliance, Challenges Hospitals to “Join the Conversation”

ASAP 340B
ASAP 340B, a coalition of a drug industry trade group and a community health center organization, added a civil rights group to its membership.

ASAP 340B, the nonprofit group that the brand drug industry and health centers formed to help advance the two sides’ joint plan to remake the 340B program, held its first webinar yesterday to describe its policy principles and call for

Read More »

News Alert

Boehringer Ingelheim Extends 340B Contract Pharmacy Conditions to All Covered Entities

Boehringer Ingelheim
Boehringer Ingelheim today stiffened its conditions on 340B pricing involving deliveries to contract pharmacies and extended them to all types of covered entities.

Drug manufacturer Boehringer Ingelheim announced this morning that, starting Aug. 1, all covered entity types will be subject to its conditions on 340B pricing when entities use contract pharmacies to dispense BI products. Until now, its conditions have applied to

Read More »

RWC-340B Slams Gilead-funded Study of 340B Grantee Entities

Shannon Burger
Shannon Burger, president of RWC-340B,, said the organization “strongly opposes" a new 340B overhaul bill.

Ryan White Clinics for 340B Access yesterday criticized drug manufacturer Gilead Sciences for sponsoring a study that said it is unclear if patients of Ryan White clinics and other 340B grantee covered entities benefit from the drug margin these entities

Read More »

JAMA Study Says, When it Comes to Insulin, Pharma’s Gross-to-Net Problem Is Mostly its Own Doing

Gross-to-net bubble for insulin
Insulin product manufacturers' take from sales is diminished more by voluntary commercial discounts than by 340B ceiling prices and other mandatory discounts, a new study found.

Drug manufacturers often observe that a growing share of their take from gross sales goes to middlemen and others in the form of rebates and discounts. A term has been coined to describe the phenomenon: the gross-to-net bubble (the difference

Read More »

News Alert

Bausch Health Tightens its Conditions on 340B Pricing to All Covered Entities

Bausch Health
Bausch Health today tightened its conditions on 340B pricing involving deliveries to contract pharmacies.

Bausch Health this morning updated its conditions on 340B pricing involving deliveries to contract pharmacies to all covered entities. It is the fifth drug maker this month to either impose such conditions for the first time (Organon and

Read More »

News Alert

Exelixis Extends 340B Price Conditions to Hospitals’ Wholly Owned Contract Pharmacies

Exelixis
Exelixis extended its conditions on 340B pricing to contract pharmacies that are wholly owned or under common ownership with a hospital covered entity.

Biopharmaceutical manufacturer Exelixis said today it is extending its conditions on 340B pricing to contract pharmacies that are wholly owned or under common ownership with a hospital covered entity. The change is effective June 26.

Exelixis announced the change in

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live